Ozempic (semaglutide) and Trulicity (dulaglutide) are prescription drugs used for people with type 2 diabetes and certain other conditions. Both drugs are injected under the skin. Ozempic and ...

Trulicity helps lower blood sugar in adults and children ages 10 years and older with type 2 diabetes. It also may reduce major heart risks in adults with type 2 diabetes who have or are at risk for ...

The U.S. Food and Drug Administration today approved Trulicity (dulaglutide), a once-weekly subcutaneous injection to improve glycemic control (blood sugar levels), along with diet and exercise, in ...

Trulicity was late to the next-generation diabetes treatment party, so Eli Lilly ($LLY) knew its launch would have to be different. The traditional U.S. strategy ...

Eli Lilly and Co. (NYSE:LLY) released topline results from SURPASS-CVOT, a head-to-head Phase 3 cardiovascular outcomes trial comparing Mounjaro (tirzepatide), a GIP/GLP-1 dual receptor agonist, to ...

SAN FRANCISCO—Back in November, news of a cardiovascular outcomes win for Trulicity pleased Eli Lilly investors whom analysts called “skeptical.” Now, those same skeptics may wonder just how well ...

Medicare Part D and some Medicare Advantage (Part C) plans may cover Trulicity for managing type 2 diabetes, but coverage specifics depend on the plan’s formulary (drug list). Medicare typically does ...

Gavreto approved for metastatic lung cancer with RET gene fusions Blueprint Medicines’ Gavreto (pralsetinib capsules) has been granted accelerated approval for treating adults with metastatic ...

TORONTO, Feb. 16, 2016 /CNW/ - Eli Lilly Canada announced the approval of Trulicity™ (dulaglutide), a once-weekly glucagon-like peptide-1 (GLP-1) receptor agonist indicated for the treatment of adults ...

Eli Lilly and Company (LLY) announced that the FDA granted approval to two higher doses, 3 mg and 4.5 mg, of its GLP-1 receptor agonist, Trulicity. The approval was based on data from the AWARD-11 ...

New Delhi: In a move to enhance its diabetes portfolio in India, US pharma major Eli Lilly has launched once-a-week diabetes treatment drug under the brand name 'Trulicity', at Rs 2,499 in the country ...